验证数据展示
经过测试的应用
| Positive FC detected in | MCF-7 cells |
推荐稀释比
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
98200-1-RR targets DDR1/CD167a in FC applications and shows reactivity with human samples.
| Tested Applications | FC Application Description |
| Tested Reactivity | human |
| Immunogen | Recombinant protein 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Full Name | discoidin domain receptor tyrosine kinase 1 |
| Synonyms | DDR1, Cell adhesion kinase, CD167a, CD167 antigen-like family member A, CD167 |
| Calculated Molecular Weight | 101kDa |
| GenBank Accession Number | NM_001297654.2 |
| Gene Symbol | DDR1 |
| Gene ID (NCBI) | 780 |
| RRID | AB_3672333 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purfication |
| UNIPROT ID | Q08345-1 |
| Storage Buffer | PBS with 0.09% sodium azide, pH 7.3. |
| Storage Conditions | Store at 2 - 8°C. Stable for one year after shipment. |
背景介绍
DDR1, or CD167a, is a member of the receptor tyrosine kinase (RTK) family, which plays a significant role in various cellular processes including cell proliferation, adhesion, migration, and extracellular matrix (ECM) remodeling. DDR1 is known for its unique discoidin domain that allows it to bind specifically to certain collagens, initiating downstream signaling pathways that can lead to cell transformation and tumor progression. Abnormal activation of DDR1 is closely associated with the development of various solid tumors, and it has been shown that DDR1 can prevent immune cells from infiltrating triple-negative breast cancer (TNBC) and eliminate tumor cells.
实验方案
| Product Specific Protocols | |
|---|---|
| FC protocol for DDR1/CD167a antibody 98200-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |